Literature DB >> 20582552

Reciprocal correlation between the expression of cyclooxygenase-2 and E-cadherin in human bladder transitional cell carcinomas.

Tae Jung Jang1, Woo Heon Cha, Kyung Seob Lee.   

Abstract

Carcinoma cells become more motile and invasive via downmodulation of E-cadherin. Cyclooxygenase-2 (COX-2) expression is associated with tumor invasion and metastasis. The aim of this study is to investigate the relationship between the expression of COX-2 and E-cadherin in a bladder cancer cell line and human bladder transitional cell carcinoma (TCCs). Phorbol 12-myristate 13-acetate (PMA) treatment for 5637 bladder cancer cells increased COX-2 expression, slightly induced Slug expression, and decreased E-cadherin expression. Ectopic expression of COX-2 or prostaglandin E(2) (PGE(2)) treatment for 5637 cells reduced E-cadherin expression. This finding was confirmed by the result that knockdown of COX-2 expression or indomethacin administration increased the expression of E-cadherin. When compared with cells' motility in serum-free medium, the treatment of PMA and PGE(2) increased cell motility, and indomethacin treatment slightly decreased cell motility. In the tissues of bladder TCCs, COX-2 expression was inversely correlated with membranous E-cadherin expression and positively correlated with nuclear beta-catenin expression. The expression of COX-2 and nuclear beta-catenin expression was significantly higher in TCCs of high grade and invasive growth than in TCCs of low grade and noninvasive growth. In contrast, membranous E-cadherin expression was more decreased in tumors of high grade and invasive growth. In addition, nuclear beta-catenin expression was significantly related to tumor recurrence. We suggest that COX-2 pathway reduces membranous E-cadherin expression in bladder TCCs and their expression pattern may provide important information in predicting the clinical behavior of bladder TCCs.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20582552     DOI: 10.1007/s00428-010-0943-3

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  32 in total

1.  Prognostic value of the expression of E-cadherin and beta-catenin in bladder cancer.

Authors:  X Garcia del Muro; A Torregrosa; J Muñoz; X Castellsagué; E Condom; F Vigués; A Arance; A Fabra; J R Germà
Journal:  Eur J Cancer       Date:  2000-02       Impact factor: 9.162

Review 2.  The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee.

Authors:  J I Epstein; M B Amin; V R Reuter; F K Mostofi
Journal:  Am J Surg Pathol       Date:  1998-12       Impact factor: 6.394

3.  Effects of etodolac, a selective cyclooxygenase-2 inhibitor, on the expression of E-cadherin-catenin complexes in gastrointestinal cell lines.

Authors:  Masao Noda; Yoichi Tatsumi; Muneta Tomizawa; Takafumi Takama; Shoji Mitsufuji; Hiroyuki Sugihara; Kei Kashima; Takanori Hattori
Journal:  J Gastroenterol       Date:  2002       Impact factor: 7.527

4.  Cyclooxygenase-2 expression increases with the stage and grade in transitional cell carcinoma of the urinary bladder.

Authors:  Pankaj Wadhwa; Anil K Goswami; Kusum Joshi; Surinder K Sharma
Journal:  Int Urol Nephrol       Date:  2005       Impact factor: 2.370

5.  Enhanced expression of cyclooxygenase-2 in high grade human transitional cell bladder carcinomas.

Authors:  M Kömhoff; Y Guan; H W Shappell; L Davis; G Jack; Y Shyr; M O Koch; S B Shappell; M D Breyer
Journal:  Am J Pathol       Date:  2000-07       Impact factor: 4.307

Review 6.  Inactivation of the E-cadherin-mediated cell adhesion system in human cancers.

Authors:  S Hirohashi
Journal:  Am J Pathol       Date:  1998-08       Impact factor: 4.307

7.  Expression of cyclooxygenase-2 in primary superficial bladder cancer tissue may predict risk of its recurrence after complete transurethral resection.

Authors:  E Okajima; H Uemura; S Ohnishi; M Tanaka; M Ohta; M Tani; K Fujimoto; S Ozono; E Okajima; Y Hirao
Journal:  Aktuelle Urol       Date:  2003-07       Impact factor: 0.658

Review 8.  The role of epithelial-mesenchymal transition in cancer pathology.

Authors:  Marcello Guarino; Barbara Rubino; Gianmario Ballabio
Journal:  Pathology       Date:  2007-06       Impact factor: 5.306

9.  Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential.

Authors:  M Tsujii; S Kawano; R N DuBois
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-01       Impact factor: 11.205

10.  Prognostic value of cadherin-associated molecules (alpha-, beta-, and gamma-catenins and p120cas) in bladder tumors.

Authors:  T Shimazui; J A Schalken; L A Giroldi; C F Jansen; H Akaza; K Koiso; F M Debruyne; P P Bringuier
Journal:  Cancer Res       Date:  1996-09-15       Impact factor: 12.701

View more
  16 in total

1.  Epithelial to mesenchymal transition in cutaneous squamous cell carcinoma is correlated with COX-2 expression but not with the presence of stromal macrophages or CD10-expressing cells.

Authors:  Tae Jung Jang
Journal:  Virchows Arch       Date:  2012-03-30       Impact factor: 4.064

2.  WHO 1973 grade 3 and infiltrative growth pattern proved, aberrant E-cadherin expression tends to be of predictive value for progression in a series of stage T1 high-grade bladder cancer after organ-sparing approach.

Authors:  Wolfgang Otto; Johannes Breyer; Sonja Herdegen; Fabian Eder; Simone Bertz; Matthias May; Roman Mayr; Eva M Lausenmeyer; Stefan Denzinger; Bas W G van Rhijn; Maximilian Burger; Arndt Hartmann
Journal:  Int Urol Nephrol       Date:  2016-12-29       Impact factor: 2.370

Review 3.  New Insights on COX-2 in Chronic Inflammation Driving Breast Cancer Growth and Metastasis.

Authors:  Honor J Hugo; C Saunders; R G Ramsay; E W Thompson
Journal:  J Mammary Gland Biol Neoplasia       Date:  2015-07-21       Impact factor: 2.673

4.  CD10 Is Again Expressed at a Certain Stage during the Neoplastic Process of Bladder Transitional Cell Carcinomas.

Authors:  Tae Jung Jang
Journal:  Cancer Res Treat       Date:  2012-12-31       Impact factor: 4.679

5.  Selective EP2 and Cox-2 inhibition suppresses cell migration by reversing epithelial-to-mesenchymal transition and Cox-2 overexpression and E-cadherin downregulation are implicated in neck metastasis of hypopharyngeal cancer.

Authors:  Yoshihiro Watanabe; Yorihisa Imanishi; Hiroyuki Ozawa; Koji Sakamoto; Ryoichi Fujii; Seiji Shigetomi; Noboru Habu; Kuninori Otsuka; Yoichiro Sato; Mariko Sekimizu; Fumihiro Ito; Yuichi Ikari; Shin Saito; Kaori Kameyama; Kaoru Ogawa
Journal:  Am J Transl Res       Date:  2020-03-15       Impact factor: 4.060

6.  Prostaglandins in cancer cell adhesion, migration, and invasion.

Authors:  David G Menter; Raymond N Dubois
Journal:  Int J Cell Biol       Date:  2012-02-29

7.  FGFR1-induced epithelial to mesenchymal transition through MAPK/PLCγ/COX-2-mediated mechanisms.

Authors:  Darren C Tomlinson; Euan W Baxter; Paul M Loadman; Mark A Hull; Margaret A Knowles
Journal:  PLoS One       Date:  2012-06-12       Impact factor: 3.240

8.  Meloxicam executes its antitumor effects against hepatocellular carcinoma in COX-2- dependent and -independent pathways.

Authors:  Xiaofeng Dong; Rui Li; Peng Xiu; Xuesong Dong; Zongzhen Xu; Bo Zhai; Feng Liu; Hongchi Jiang; Xueying Sun; Jie Li; Haiquan Qiao
Journal:  PLoS One       Date:  2014-03-27       Impact factor: 3.240

9.  Prostaglandin E(2) and interleukin-1β reduce E-cadherin expression by enhancing snail expression in gastric cancer cells.

Authors:  Ye Seob Jee; Tae Jung Jang; Ki Hoon Jung
Journal:  J Korean Med Sci       Date:  2012-08-22       Impact factor: 2.153

10.  Restoration of E-cadherin expression by selective Cox-2 inhibition and the clinical relevance of the epithelial-to-mesenchymal transition in head and neck squamous cell carcinoma.

Authors:  Ryoichi Fujii; Yorihisa Imanishi; Katsushi Shibata; Nobuya Sakai; Koji Sakamoto; Seiji Shigetomi; Noboru Habu; Kuninori Otsuka; Yoichiro Sato; Yoshihiro Watanabe; Hiroyuki Ozawa; Toshiki Tomita; Kaori Kameyama; Masato Fujii; Kaoru Ogawa
Journal:  J Exp Clin Cancer Res       Date:  2014-05-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.